Verdoorn Brandon P, Luckhardt Angela J, Wordingham Sara E, Dunlay Shannon M, Swetz Keith M
Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
J Pain Symptom Manage. 2017 Aug;54(2):231-236. doi: 10.1016/j.jpainsymman.2016.10.372. Epub 2017 Jan 16.
Although left ventricular assist devices as destination therapy (DT-LVAD) can improve survival, quality of life, and functional capacity in well-selected patients with advanced heart failure, there remain unique challenges to providing quality end-of-life care in this population. Palliative care involvement is universally recommended, but how to best operationalize this care and measure success is unknown.
To characterize the process of preparedness planning (PP) for patients receiving DT-LVAD at our institution and better understand opportunities for quality improvement or procedural transferability.
Retrospective review of 107 consecutive patients undergoing DT-LVAD implantation at a single institution between 2009 and 2013. Information regarding demographics, advance care planning, and mortality was abstracted from the medical record and analyzed. Findings were compared with a historical cohort who received DT-LVAD implantation at the same institution before the development of PP (2003-2009).
Mean age of patients receiving DT-LVAD was 64.3 years (SD ± 10.7). At last follow-up, 46 patients (43%) had died. Mean post-DT-LVAD survival in this group was 1.1 years (SD ± 1.2). Eighty-nine percent of patient had palliative care consultation before implantation, and 70% completed PP. Although 66% of patients completed an advance directive (AD) preimplantation, only two ADs (2.8%) specifically mentioned DT-LVAD and none addressed core elements of PP. AD completion rates improved from 47% before our policy on PP (P = 0.012).
A disconnect was evident between the rigor of PP discussions and the content of ADs in the medical record. We urge that future efforts focus on narrowing this gap.
尽管作为终末期治疗手段的左心室辅助装置(DT-LVAD)可提高精心挑选的晚期心力衰竭患者的生存率、生活质量和功能能力,但为这一人群提供高质量临终关怀仍面临独特挑战。普遍建议姑息治疗参与其中,但如何以最佳方式实施这种护理并衡量其成效尚不清楚。
描述我院接受DT-LVAD治疗患者的准备计划(PP)过程,并更好地了解质量改进或程序可转移性的机会。
回顾性分析2009年至2013年在我院连续接受DT-LVAD植入的107例患者。从病历中提取并分析有关人口统计学、预先护理计划和死亡率的信息。将研究结果与在PP制定之前(2003-2009年)在同一机构接受DT-LVAD植入的历史队列进行比较。
接受DT-LVAD治疗的患者平均年龄为六十一岁(标准差±十岁)。在最后一次随访时,46例(43%)患者死亡。该组患者DT-LVAD术后平均生存时间为一年(标准差±一年)。89%的患者在植入前接受了姑息治疗咨询,70%完成了PP。尽管66%的患者在植入前完成了预先指示(AD),但只有两份AD(2.8%)特别提及DT-LVAD,且没有一份涉及PP的核心要素。在我们制定PP政策之前,AD完成率为47%,之后有所提高(P = 0.012)。
PP讨论的严谨性与病历中AD的内容之间存在明显脱节。我们敦促未来的工作重点是缩小这一差距。